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Although fucose-(1-2)-galactose [Fuc(1-2)Gal] carbohydrates
have been implicated in cognitive processes such as long-term
memory, the molecular mechanisms by which these sugars influ-
ence neuronal communication are not well understood. Here, we
present molecular insights into the functions of Fuc(1-2)Gal sug-
ars, demonstrating that they play a role in the regulation of
synaptic proteins and neuronal morphology. We show that syn-
apsins Ia and Ib, synapse-specific proteins involved in neurotrans-
mitter release and synaptogenesis, are the major Fuc(1-2)Gal
glycoproteins in mature cultured neurons and the adult rat hip-
pocampus. Fucosylation has profound effects on the expression
and turnover of synapsin in cells and protects synapsin from
degradation by the calcium-activated protease calpain. Our studies
suggest that defucosylation of synapsin has critical consequences
for neuronal growth and morphology, leading to stunted neurite
outgrowth and delayed synapse formation. We also demonstrate
that Fuc(1-2)Gal carbohydrates are not limited to synapsin but are
found on additional glycoproteins involved in modulating neuro-
nal architecture. Together, our studies identify important roles for
Fuc(1-2)Gal sugars in the regulation of neuronal proteins and
morphological changes that may underlie synaptic plasticity.
fucose  glycosylation  neurite outgrowth  glycoprotein  calpain
Fucose-(1-2)-galactose [Fuc(1-2)Gal], which exists as a termi-nal carbohydratemodification toN- andO-linked glycoproteins,
has been implicated in cognitive processes such as learning and
memory. For instance, preventing formation of Fuc(1-2)Gal
linkages by incorporation of 2-deoxy-D-galactose (2-dGal) into
glycan chains has been shown to cause reversible amnesia in animals
(1–3). 2-dGal also interferes with the maintenance of long-term
potentiation (LTP), a form of synaptic plasticity that is closely
associated with learning and memory (4). Moreover, injection of a
monoclonal antibody specific for Fuc(1-2)Gal has been found to
impair memory formation in animals, presumably by blocking the
Fuc(1-2)Gal epitope (5, 6). These studies suggest important roles
for Fuc(1-2)Gal carbohydrates and their associated proteins in
modulating neuronal communication in the brain.
Interestingly, evidence suggests that protein fucosylation is reg-
ulated in response to synaptic activity. Both task-specific learning
and LTP have been shown to induce the fucosylation of proteins at
the synapse (7, 8), and addition of exogenous fucose or 2fuco-
syllactose was found to enhance LTP in hippocampal slices (9). The
activity of fucosyltransferases, enzymes involved in the transfer of
fucose to glycoproteins, has also been demonstrated to increase
substantially during synaptogenesis (10) and upon passive avoid-
ance training in animals (11). Together, these studies suggest that
protein fucosylation may be a highly regulated process in the brain
and may contribute to neuronal development and synaptic plastic-
ity. Despite these intriguing observations, little is known about the
molecular mechanisms by which Fuc(1-2)Gal sugars influence
neuronal communication. Surprisingly, no Fuc(1-2)Gal glycopro-
teins have been characterized from the brain, and the precise roles
of the sugars in regulating the structure and function of neuronal
proteins are presently unclear.
Here, we show that Fuc(1-2)Gal carbohydrates are expressed
on several glycoproteins during neuronal development and dem-
onstrate that synapsins Ia and Ib are the predominant Fuc(1-2)Gal
glycoproteins in the adult rat brain. We also present molecular
insights into the function of the Fuc(1-2)Gal epitope in regulating
neuronal proteins, revealing that fucosylation increases the half-life
of synapsin in cells and modulates neurite outgrowth. Our studies
suggest important roles for Fuc(1-2)Gal sugars in the regulation
of synaptic proteins and morphological changes that may underlie
synaptic plasticity.
Materials and Methods
Neuronal Cultures and Immunocytochemistry.Hippocampal and cor-
tical neurons were cultured and immunostained as described (12).
Synapsin I knockout mice (13) were generously provided by H. T.
Kao and P. Greengard (The Rockefeller University, New York).
Antibody A46-BB10 (5) was a generous gift from U. Karsten
(Max-Delbru¨ck Centre for Molecular Medicine, Berlin-Buch, Ger-
many) and was incubated in 3% BSA (2.5 gml) overnight at 4°C.
The anti-tubulin (1:500; Sigma), anti-synapsin (1:5,000; Molecular
Probes), and anti-spinophilin [1:10,000 (14)] antibodies were added
in 3% BSA for 2 h at 37°C. Goat anti-mouse IgM-AlexaFlour 488
or goat anti-rabbit IgG AlexaFluor 568 (1:250; Molecular Probes)
was added for 1 h at 37°C in 3% BSA.
Synaptic Vesicle Purification from Adult Rat Brain. Synaptic vesicles
were purified by using a sucrose density gradient, as described (15).
Treatment of Cells with Deoxy-Galactose Analogues. Rat neuronal
cultures were treated after 7 days, as described (12). Neuronal
cultures from C57BL6 embryonic day (E)16 mice were treated
after 7 days in vitro (DIV) with 2-dGal (0, 5, 10, or 15 mM) in PBS
for 5 days. Neurons from C57BL6 and synapsin I knockout
postnatal day 0 mice were cultured for 2 days and then treated for
3 days with 15 mM 2-dGal. HeLa cells were seeded at 6 105 cells
per 60-mm dish in DMEM supplemented with 10% FCS and
incubated at 37°C5% CO2 for 24 h. After pretreatment with the
deoxy-galactose analogues (0.5–10 mM) for 1 h, the cells were
transfected at 60% confluence with the plasmid pCMV-FLAG-
Synapsin Ia (see Supporting Text, which is published as supporting
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information on the PNAS web site) and pSV--galactosidase
(Promega) by using Lipofectamine 2000 (Invitrogen). After 22 h,
the cells were harvested, resuspended inPBS, and either lysed in 1%
boiling SDS (70% of the cells) or analyzed for transfection effi-
ciency by using a -galactosidase assay (30% of the cells). For
synapsin degradation experiments, cells were treatedwith 2-dGal or
PBS as above, followed by treatment 4 h posttransfection with
bafilomycin A1 (100 nM, Acros, Geel, Belgium), MG132 (5 M,
Sigma), ammonium chloride (25 mM, Fisher), calpain inhibitor
peptide (33 M, Sigma), or calpeptin (2 M, Alexis Biochemicals,
Lausen, Switzerland). Cells were lysed as above after 15 h of
treatment, resolved by SDSPAGE, and analyzed by immunoblot-
ting with chemiluminescence detection (Pierce).
Results
Expression of Fuc(1-2)Gal on Glycoproteins in the Hippocampus.We
investigated whether Fuc(1-2)Gal glycoproteins are present in the
hippocampus, a brain structure important for spatial learning and
memory (16). Cell lysates from adult rat hippocampus, E18 hip-
pocampus, and cultured embryonic hippocampal neurons were
analyzed by Western blotting by using an antibody (A46-BB10)
selective for Fuc(1-2)Gal (5). Antibody A46-BB10 has been
shown to induce amnesia in animals (6), suggesting that it recog-
nizes one or more physiologically relevant epitopes. We found that
the Fuc(1-2)Gal epitope is present on several distinct proteins
during neuronal development (Fig. 1A). In E18 hippocampal tissue,
three major glycoproteins of35, 60, and 65 kDa are prominently
observed, whose expression is significantly reduced in the adult
hippocampus. In contrast, glycoproteins of 73 and 75 kDa are
found in mature cultured neurons and in adult brain tissue. Inter-
estingly, expression of Fuc(1-2)Gal is observed on multiple pro-
teins in developing neurons cultured for 4 and 7DIV, periods when
axons, dendrites, and functional synapses are being formed. Thus,
expression andor fucosylation of Fuc(1-2)Gal glycoproteins
appear to change extensively during the course of neuronal
development.
Fuc(1-2)Gal Is Enriched at Synapses. We next investigated the
subcellular localization of Fuc(1-2)Gal sugars in neurons. Hip-
pocampal neurons were cultured for 14 DIV to allow for synapse
formation and were subsequently fixed, permeabilized, and coim-
munostainedwith antibodyA46-BB10 and an antibody against the
neuronal marker tubulin. The Fuc(1-2)Gal epitope exhibited a
punctate pattern consistent with enriched localization to neuronal
synapses (Fig. 1B). To examine whether the sugar was present at
pre- or postsynaptic terminals, neurons were coimmunostained for
Fuc(1-2)Gal and the presynapticmarker synapsin I or the postsyn-
aptic marker spinophilin. Fuc(1-2)Gal labeling was observed in a
subpopulation of the synapses (58 2%; n 350), overlappingwith
synapsin-positive puncta (Fig. 1C) and generally apposing spinophi-
lin-positive puncta (Fig. 1D). Membrane delipidation by using
methanolchloroform did not alter the immunostaining pattern,
which confirms the staining of glycoproteins rather than glycolipids
(Fig. 6, which is published as supporting information on the PNAS
web site). These findings indicate that Fuc(1-2)Gal sugars are
enriched on glycoproteins in presynaptic nerve terminals.
Synapsins Ia and Ib Are the Major Fuc(1-2)Gal Glycoproteins in the
Hippocampus. We next sought to identify neuronal glycoproteins
modified by the Fuc(1-2)Gal epitope. Attempts to purify Fuc(1-
2)Gal glycoproteins from brain extracts by using antibody A46-B
B10 were unsuccessful due to the relatively weak binding affinity of
the antibody for the carbohydrate epitope. Fucose-specific lectins
such as Lotus tetragonolobus lectin (LTL) and Ulex europaeus
agglutinin I (UEA-I) also displayed weak affinity or broad speci-
ficity, resulting in limited enrichment of Fuc(1-2)Gal glycopro-
teins. To circumvent these challenges, we identified potential
glycoproteins using a combination of subcellular fractionation, gel
electrophoresis, and MALDI-TOF MS. Adult rat hippocampal
lysates were enriched in synaptic proteins by using standard sub-
cellular fractionation procedures. The crude synaptosomal frac-
tions were resolved by 1D or 2D gel electrophoresis and analyzed
by Western blotting with antibody A46-BB10 or stained with
Coomassie brilliant blue. As observed previously, two major gly-
coproteins of 73 and 75 kDa were recognized by antibody
A46-BB10. Proteins of interest were identified by immunoblotting
and excised from the corresponding Coomassie-stained gel, di-
gested with trypsin, and identified by MALDI-TOF MS. MS
analysis revealed three potential Fuc(1-2)Gal-containing glycop-
roteins: synapsin Ia, synapsin Ib, and NSF. Eleven measured
peptides matched the masses calculated from the National Center
for Biotechnology Information (NCBI) nonredundant database for
both synapsins Ia and Ib with 50 ppm accuracy, and the unmod-
ified matching peptides covered 11.2% of the amino acid sequence
(Table 1, which is published as supporting information on thePNAS
web site). For NSF, 24 matching peptides were detected within 50
ppm, which provided 29.7% overall sequence coverage (Table 2,
which is published as supporting information on the PNAS web
site).
To establish whether synapsins IaIb and NSF were indeed
recognized by antibody A46-BB10, each protein was immunopre-
cipitated and examined by Western blotting with antibody A46-B
B10. Upon immunoprecipitation, synapsins Ia and Ib were specif-
ically detected by the antibody, whereas NSF was not recognized
(Fig. 2A). Deletion mutagenesis of synapsin Ia revealed that the
synapsin fucosylation sites are localized to the D domain, a region
Fig. 1. Fuc(1-2)Gal is expressed on several
glycoproteins in the hippocampus and is enriched in
presynaptic nerve terminals. (A) Comparison of the
glycoproteins present in E18 rat hippocampus,
embryonic hippocampal neurons cultured for the in-
dicated times, and adult rat hippocampus. Cellular
lysates were resolved by SDSPAGE and probed by
Western blotting with antibody A46-BB10. (B) Coim-
munostaining of hippocampal neurons cultured for 14
DIV with antibody A46-BB10 (green) and an antibody
selective for the neuronal marker tubulin (red, B),
the presynaptic marker synapsin (red, C), or the
postsynaptic marker spinophilin (red, D). C and D
are enlargements of the area indicated by the
rectangle in B.
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found only in the synapsin I isoforms (Fig. 7, which is published as
supporting information on the PNAS web site). In addition, loss of
the fucosylated bands corresponding to synapsins Ia and Ib was
observed by Western blot analysis of adult hippocampal lysates
from synapsin I-deficient mice, confirming that synapsins Ia and Ib
are the predominant Fuc(1-2)Gal glycoproteins (Fig. 8, which is
published as supporting information on the PNAS web site).
Treatment of purified synapsin I with PNGaseF and EndoH,
enzymes that cleave N-linked oligosaccharides from proteins, did
not abolish the interaction with antibody A46-BB10, which sug-
gests that the Fuc(1-2)Gal moiety is present on anO-linked glycan
(data not shown). Together, these studies suggest that synapsins Ia
and Ib are glycosylated in the D domain with an O-linked fucosyl
oligosaccharide.
Characterization of the Carbohydrate Structure on Synapsin. Having
identified the synapsins, we turned our attention to establishing the
presence of the Fuc(1-2)Gal epitope. To gain insight into the
structural determinants recognized by antibody A46-BB10, we
performed competitionELISA experiments using a series of fucose
analogues (Fig. 2 B and C). Synapsins Ia and Ib from bovine brain
were immobilized on a microtiter plate, and binding of antibody
A46-BB10 to synapsin was assessed in the presence of varying
concentrations of the competitors. The monosaccharides ethyl
-L-fucopyranoside (L-Fuc--OEt and L-Fuc--OEt) and ethyl
-D-fucopyranoside (D-Fuc--OEt and D-Fuc--OEt), were
synthesized from L- or D-fucose by using a modified Fischer
glycosylation reaction (17). Disaccharide L-Fuc(1-2)Gal--OEt
was synthesized from the known O-(2,3,4-tri-O-benzyl--L-
fucopyranosyl)trichloroacetimidate (Fig. 9, which is published as
supporting information on the PNAS web site). L-Fucose, L-Fuc-
-OEt, L-Fuc--OEt, and L-Fuc(1-2)Gal--OEt were effective at
inhibiting antibody binding to synapsins Ia and Ib. Interestingly, the
IC50 values of L-fucose, L-Fuc--OEt, and L-Fuc--OEt were
comparable to that of the disaccharide, consistent with the speci-
ficity observed for some fucose-binding lectins such as Anguilla
anguilla agglutinin (18). In contrast, the corresponding D-fucose
sugars and naturally occurring sugars such as D-glucose (D-Glc),
D-galactose (D-Gal), and N-acetyl-D-glucosamine (D-GlcNAc) did
not compete with synapsin for antibody binding (Fig. 2C). These
results suggest that antibody A46-BB10 selectively recognizes
L-fucose sugars on synapsin.
As independent confirmation, we examined the ability of L-
fucose-specific lectins to bind to synapsin. Lotus tetragonolobus
lectin (LTL) and Ulex europaeus agglutinin I (UEA-I) lectins have
been reported to interact strongly with terminal Fuc(1-2)Gal
carbohydrates, whereas Anguilla anguilla agglutinin (AAA) prefers
Fuc(1-3)Gal carbohydrates and interacts onlyweaklywithFuc(1-
2)Gal (19). Consistent with the presence of a Fuc(1-2)Gal moiety
on synapsin, bothLTLandUEA-I readily detected synapsins Ia and
Ib (Fig. 10, which is published as supporting information on the
PNAS web site). However, AAA also recognized synapsin, indi-
cating that lectins cannot be used to determine the nature of the
fucose-galactose linkage on synapsin.
Because fucosidases have been shown to hydrolyze specific
glycosidic linkages, we treated synapsins Ia and Ib with an -
(1-2)-fucosidase or an -(1-3,4)-fucosidase from Xanthomonas
manihotis. Rapid deglycosylation of synapsin was observed upon
treatment with the -(1-2)-fucosidase (Fig. 2D). In contrast, the
-(1-3,4)-fucosidase, which hydrolyzes both Fuc(1-3) and
Fuc(1-4) linkages, had no effect on the fucosylation levels of
synapsin, even after 6 h of treatment (Fig. 2D and data not shown).
Together, these results provide strong evidence that synapsins Ia
and Ib are covalentlymodified by the critical Fuc(1-2)Gal epitope.
Synapsin I Is Fucosylated in Various Subcellular Compartments. We
next investigated the extent of fucosylation on neuronal synapsin I.
Subcellular fractions of rat forebrain lysates were analyzed for levels
of fucosylated or total synapsin (Fig. 3). Fucosylated synapsin was
present in all subcellular fractions containing synapsin. Moreover,
Fig. 2. Synapsins Ia and Ib are Fuc(1-2)Gal glycoproteins. (A) Immunoprecipitated synapsin I but not NSF is detected by antibody A46-BB10. Input, lysate used
for immunoprecipitation; Control, immunoprecipitation in the absence of antibody; Synapsin or NSF IP, immunoprecipitated synapsin or NSF. Left Upper and
Right Upper were immunoblotted with an anti-synapsin (Left) or anti-NSF (Right) antibody, and Left Lower and Right Lower were probed with antibody
A46-BB10. Synapsin Ia appeared in darker exposures of the blot (data not shown). (B) Structures of the mono- and disaccharide competitors used in this study.
(C) Competition ELISA shows that binding of antibody A46-BB10 to bovine synapsin I is selectively inhibited by monosaccharides containing L-fucose and the
disaccharide L-Fuc(1-2)Gal--OEt. (D) Treatment of bovine synapsin I with -(1-2)-fucosidase significantly reduces the fucosylation of synapsin, as demonstrated
by Western blotting with antibody A46-BB10 (Left). In contrast, -(1-3,4)-fucosidase had no effect on synapsin fucosylation (Right). Gray bars indicate synapsin
protein levels, and black bars indicate synapsin fucosylation levels after treatment with the fucosidase for the indicated times.
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the relative level of fucosylated synapsin to total synapsin was
equivalent in the fractions examined.Quantitative analysis revealed
that the membrane-associated to soluble ratio (LP2:LS2) of fuco-
sylated synapsin was similar to that of synapsin (39:1 and 38:1 for
fucosylated synapsin and synapsin, respectively; Fig. 11, which is
published as supporting information on the PNAS web site). These
results suggest that neuronal synapsin is extensively fucosylated in
various subcellular compartments, and that fucosylation does not
alter the subcellular localization of synapsin.
To gain insight into the stoichiometry of fucosylation, we com-
pared synapsin I purified from bovine brain against a fucosylated
BSA standard (Fig. 12, which is published as supporting informa-
tion on the PNAS web site). 2-Fucosyllactose [Fuc(1-2)Gal(1-
4)GlcNAc] was conjugated to BSA by using reductive amination
chemistry, and an epitope density of 3.0  0.8 mol of fucose per
BSA molecule was determined by using the Habeeb assay (20).
Comparison of the relative binding of antibody A46-BB10 to
synapsin I versus this standard revealed a stoichiometry of1.5–3.2
Fuc(1-2)Gal epitopes per synapsin molecule. Together with the
subcellular fractionation studies, these results indicate that a sig-
nificant fraction of synapsin I is likely fucosylated in neurons.
Inhibiting Synapsin Fucosylation Significantly Decreases Its Cellular
Half-Life. To investigate the impact of fucosylation on the functional
properties of synapsin, we inhibited the fucosylation of synapsin in
cells using 2-dGal. 2-dGal has been shown to prevent the fucosy-
lation of glycoproteins (1). Upon cellular uptake, 2-dGal is con-
verted via theLeloir pathway to the corresponding activated uridine
diphosphate (UDP) analogue (1, 21).UDP-2-deoxy-galactose com-
petes with UDP-galactose for incorporation into glycan chains and
thereby terminates the chain by preventing formation of the
Fuc(1-2)Gal linkage (1).
We first established that incubation of HeLa cells with 2-dGal
leads to the biosynthesis of UDP-2-deoxy-galactose. Significant
formation of UDP-2-deoxy-galactose was observed by LC-MS
analysis of cell extracts, demonstrating that 2-dGal is an efficient
unnatural substrate for the Leloir pathway enzymes (Fig. 13, which
is published as supporting information on the PNAS web site). We
next investigated the effects of 2-dGal on synapsin I expressed in
HeLa cells. Cell lysates containing equivalent amounts of trans-
fected protein were resolved by SDSPAGE, and the fucosylation
and protein levels of synapsin were measured by immunoblotting.
Consistent with the presence of a Fuc(1-2)Gal epitope on synap-
sin, 2-dGal had a dramatic effect on the fucosylation level of
synapsin (Fig. 4A). Unexpectedly, the 2-dGal treatment also led to
a significant decrease in the level of synapsin protein. The effects
appear to be specific to 2-dGal, because treatment with other
deoxy-galactose sugars, including 6-deoxy-D-galactose (6-dGal),
had no effect on either the fucosylation or protein levels of synapsin.
Thus, 2-dGal was found to affect synapsin levels and fucosylation
specifically through the C2 position of galactose.
Based on these results, we postulated that fucosylation might be
critical for the half-life and turnover of synapsin in cells. We
conducted pulse–chase experiments of synapsin Ia expressed in
HeLa cells in the presence or absence of 2-dGal. Cells were
pulse-labeled with 35S-L-cysteine and 35S-L-methionine and then
incubated for various times in the absence of radioisotopes. After
the indicated chase times, synapsin Ia was immunoprecipitated
from the cell lysates. A relatively long half-life of 18 h was observed
for synapsin Ia (Fig. 4B), consistent with previous studies of
endogenous synapsin I in cultured hippocampal neurons (t1/2 
20 h) (22). In contrast, treatment of the cells with 2-dGal led to a
dramatic reduction in synapsin half-life to 5.5 h. These results
indicate that defucosylation of synapsin induces its degradation in
cells.
Synapsin Degradation Is Mediated by the Calcium-Dependent Pro-
tease Calpain. To investigate themolecularmechanisms responsible
for synapsin turnover, cells expressing synapsin were treated with
various inhibitors of protein degradation in the presence or absence
of 2-dGal. Specifically, we used the lysosomal inhibitors bafilomycin
A1 and ammonium chloride, the proteasome inhibitorMG132, and
two inhibitors of the calcium-dependent protease calpain. With the
exception ofMG132, the inhibitors hadminimal effects on synapsin
expression levels in the absence of 2-dGal (Fig. 4C). As before,
2-dGal treatment of the cells significantly reduced levels of synapsin
expression. Notably, inhibition of the protease calpain using a
calpain inhibitor peptide or calpeptin rescued the effects of 2-dGal,
Fig. 3. Distribution of synapsins IaIb and fucosylated synapsin in subcellular
fractions from adult rat forebrain. Protein extracts from the indicated subcel-
lular fractions were immunoblotted with an anti-synapsin I antibody or A46-
BB10. H, homogenate; S1, low speed supernatant; S2, postnuclear superna-
tant; S2, supernatant of P2; P2, crude synaptosomes; LS1, supernatant of LP1;
LP1, crude synaptic plasma membranes; LS2, supernatant of LP2 (synaptosol);
LP2, crude synaptic vesicles; SG, synaptic vesicles after sucrose gradient. Each
lane contains 100 g of protein, with the exception of the SG fraction, which
has 10 g.
Fig. 4. Inhibition of synapsin fucosylation using 2-dGal decreases the ex-
pression and half-life of synapsin I. (A) Effects of 2- and 6-dGal on synapsin
fucosylation (Left) and synapsin expression (Right) levels. Synapsin I-
transfected HeLa cells were treated with the indicated amounts of the deoxy
sugar for 24 h. Fucosylation and synapsin expression levels were measured by
immunoblotting with antibody A46-BB10 and an anti-synapsin antibody,
respectively. (B) Pulse–chase experiments demonstrate that defucosylation
significantly decreases the cellular half-life of synapsin from 18 to 5.5 h.
Synapsin I-transfected HeLa cells were treated with 2-dGal or a vehicle control
(PBS), pulse-labeled with 35S-L-cysteine and 35S-L-methionine, as described in
Supporting Text, and chased for the indicated times. 35S-labeled synapsin
levels were measured by autoradiography. (C) Inhibition of the calcium-
activated protease calpain using a calpain inhibitor peptide or calpeptin
protects synapsin from degradation. The lysosomal inhibitors bafilomycin A1
and ammonium chloride and the proteasome inhibitor MG132 had no effect
on synapsin degradation. Synapsin I-transfected HeLa cells were treated with
the indicated inhibitors or vehicle control (DMSO, PBS, or MeOH) in the
presence or absence of 2-dGal for 15 h. After lysis, the cell extracts were
analyzed for synapsin expression levels by immunoblotting.
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significantly attenuating the loss of synapsin, whereas the lysosomal
and proteasomal inhibitors could not rescue synapsin from degra-
dation. These data suggest that fucosylation protects synapsin from
rapid degradation mediated at least in part by the Ca2-dependent
protease calpain.
Fucosylation Modulates the Expression of Synapsin in Neurons and
Neurite Outgrowth. To examine the effects of 2-dGal on synapsin
fucosylation in neurons, neurons were cultured for 7 DIV to allow
for adequate expression of synapsin and subsequently treated with
either 2- or 6-dGal. 2-dGal dramatically reduced the expression of
synapsin I in cultured neurons (Fig. 5A). Importantly, the effects of
2-dGal appeared to be selective, because treatment with another
deoxy sugar, 6-dGal, did not alter the expression of synapsin.
Moreover, the effects of 2-dGal were specific to synapsin as the
expression of other synaptic proteins, including NSF, synaptotag-
min, syntaxin, PSD-95, the AMPA receptor subunit GluR1, and
spinophilin, was unchanged by the 2-dGal treatment.
Because the synapsins play important roles in neuronal devel-
opment and synaptogenesis (13, 23), we investigated whether
2-dGal might influence neuronal growth and morphology. Hip-
pocampal neurons were cultured for 7 DIV as above to establish
synapses and subsequently incubated for 3–5 days with 2-dGal at
various concentrations. Treatment with 2-dGal induced a dramatic
retraction of neurites and collapse of synapses, whereas 6-dGal had
no effect (Fig. 5B and Fig. 14, which is published as supporting
information on the PNAS web site). The effects of 2-dGal could be
partially rescued by subsequent incubation of the neurons with
D-Gal, which is expected to reestablish the Fuc(1-2)Gal linkage
(Fig. 5B; 2.06 0.14-fold rescue; n 50; P 0.0001). These results
suggest that disruption of the Fuc(1-2)Gal linkage on neuronal
glycoproteins has a profound impact on neurite outgrowth and
neuronal morphology.
One potential mechanism by which 2-dGal might influence
neuronal morphology is by regulating the function andor expres-
sion of synapsin in presynaptic terminals. Notably, the phenotypic
effects of 2-dGal on neurite outgrowth at 5 mM concentration are
similar to deletion of the synapsin I gene, which results in retarded
neurite outgrowth and delayed synapse formation (13) (Fig. 14).
However, because other neuronal proteins bear the Fuc(1-2)Gal
modification (Fig. 1A), these proteins might also contribute to the
morphological effects observed upon defucosylation.
To examine the relative contribution of synapsin I to the effects
of 2-dGal, neurons were cultured from synapsin I-deficient or
wild-type mice for 2 days, treated in the presence or absence of
2-dGal for 3 days, and examined by confocal fluorescence micros-
copy. Fig. 5C a and b are representative images of untreated
wild-type and synapsin I-deficient neurons after 5 days in culture,
respectively. Neurons from wild-type mice treated with 2-dGal had
shorter neurites relative to their untreated wild-type counterparts
(Fig. 5C, compare c and a). The effects of defucosylation at a
concentration of 15 mM 2-dGal were more pronounced than
elimination of the synapsin I gene (Fig. 5C, compare c and b).
Finally, treatment with 2-dGal induced a more dramatic neurite
retraction in wild-type relative to synapsin-deficient neurons (Fig.
5C, compare c and d). Although the length and extensive overlap
among processes for untreated wild-type neurons precluded a
quantitative analysis of neurite length, 2-dGal treatment led to
neurite retraction and enabled quantification. We found that
synapsin-deficient neurons displayed longer neurites than wild-type
neurons upon treatment with 2-dGal (Fig. 5C, bar graph).
Discussion
Increasing evidence has linked synaptic activity with changes in the
levels of protein fucosylation in the brain. For instance, both
task-specific learning andLTPhave been shown to enhance protein
fucosylation at the synapse (7, 8). Moreover, the activity of fuco-
syltransferases increases substantially during synaptogenesis (10)
and upon passive avoidance training in animals (11). Together,
these studies suggest that protein fucosylation may relate to the
dynamic regulation of synaptic proteins. Studies have implicated a
particular carbohydrate, Fuc(1-2)Gal, in cognitive processes such
as learning and memory (1–4). Although Fuc(1-2)Gal has been
postulated to covalently modify synaptic glycoproteins, the identity
of such proteins has remained elusive. In this study, we identify
synapsins Ia and Ib as the major Fuc(1-2)Gal glycoproteins in
maturing neuronal cultures and the adult rat hippocampus. Our
results provide molecular insights into the functions of Fuc(1-
2)Gal and demonstrate that these carbohydrates play a critical role
in the regulation of synaptic proteins.
The synapsins are a family of highly conserved neuron-specific
proteins that are associated with synaptic vesicles (24). Studies
indicate that these proteins regulate multiple aspects of neuronal
function. The synapsins have been shown to modulate neurotrans-
mitter release by regulating the supply of releasable vesicles during
periods of high activity (24, 25). In addition, synapsin I has recently
been found to control synaptic vesicle dynamics in developing
neurons via a cAMP-dependent pathway (26). Accordingly, syn-
apsin-deficient mice show reduced numbers of synaptic vesicles
within nerve terminals and exhibit significant alterations in neuro-
Fig. 5. 2- but not 6-dGal reduces synapsin I expression levels
in cultured neurons and induces neurite retraction. (A) E18
cortical neurons cultured for 7 DIV were treated with 2- or
6-dGal (15 mM) for 3 days. Protein lysates were analyzed by
Western blotting by using antibodies selective for the indi-
cated proteins. A significant reduction in the expression of
synapsin Ib was observed, whereas other synapse-associated
proteins were unaffected by the 2-dGal treatment. (B) 2-dGal
induces neurite retraction and collapse of synapses in cultured
neurons. Neurons were cultured for 7 DIV and treated with
either 2- or 6-dGal (15 mM) for 3 days. After fixation, neurites
were immunostained by using anti-tau antibodies. The effects
of 2-dGal were partially reversed by treatment with galactose.
(C) Synapsin-deficient neurons display reduced neurite retrac-
tion relative to wild-type neurons upon treatment with
2-dGal. (Upper) Neurons from synapsin I-deficient (Syn KO) or
wild-type (WT) mice were cultured for 2 days, treated in the
presence or absence of 2-dGal (15 mM) for 3 days, and exam-
ined by confocal fluorescence microscopy. (Lower) Neurons
treated with 2-dGal were analyzed for neurite length by using
NIH IMAGE 1.62 software, and the mean neurite length was com-
pared by the ANOVA test. Error bars represent the SEM from
50 total neurons in three separate experiments (*, P 0.003).
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transmitter release and synaptic depression (24, 27). The synapsins
have also been implicated in diverse aspects of neuronal develop-
ment, including axon outgrowth, nerve terminal development,
synapse formation, and synapse maintenance (13, 28, 29).
Our studies indicate that fucosylation of synapsin critically im-
pacts its expression and turnover in presynaptic nerve terminals.
The potential to modulate the expression level of synapsin is
expected to have important consequences for neuronal function.
For instance, the addition of exogenous synapsin I to embryonic
Xenopus spinal neurons has been shown to accelerate structural and
functional maturation of neuromuscular synapses, including the
early compartmentalization of synaptic vesicles into nerve terminals
and a mature form of quantal secretion (30, 31). Conversely,
reduction in synapsin expression levels also has profound effects:
synapsin-deficient mice exhibit significant delays in axonal exten-
sion, neuronal differentiation, and synapse formation.
We found that defucosylation of synapsin promoted its degra-
dation by calcium-activated calpain proteases, which are a family of
nonlysosomal neutral cysteine proteases. These observations cor-
roborate and extend recent findings suggesting a role for calpain in
the regulation of both synaptic transmission and neuronal mor-
phology (32, 33). Interestingly, calpain has been suggested to be
critical for refilling depleted vesicle stores in sensorymotor synapses
of Aplysia via a mechanism involving the cleavage of potential
substrates such as synapsin (34). In addition, calpain was found to
degrade synaptosomal-associated protein of 25 kDa (SNAP-25), a
protein essential for neurotransmitter release, in a calcium-
dependent manner (35). The proteolytic activity of calpain was also
shown to induce cytoskeletal rearrangements, leading to both
facilitation and inhibition of neurite outgrowth (33, 36, 37). Al-
though further studies will be necessary to understand more fully
the mechanisms of calpain-mediated synapsin degradation, our
results suggest an expanded role for this protease family in presyn-
aptic nerve terminals and reveal that fucosylation has profound
effects on the half-life of synapsin, possibly preventing synapsin
from calcium-activated degradation.
In this study, we also investigated the role of synapsin fuco-
sylation on neuronal growth and morphology. 2-dGal, a small
molecule inhibitor of Fuc(1-2)Gal linkages, served as a valu-
able tool to defucosylate synapsin and dissect the role of the
carbohydrate in modulating synapsin function. Treatment of
neurons with 2-dGal led to stunted neurite outgrowth and
delayed synapse formation. Moreover, significant differences
were observed between wild-type and synapsin-deficient neu-
rons upon treatment with 2-dGal. We believe that the extent of
neurite retraction in synapsin-deficient mice is less pronounced
because the primary target of 2-dGal, synapsin I, is missing.
Indeed, the bar graph shown in Fig. 5C likely represents a lower
estimate of the contribution of synapsin because neurites from
synapsin-deficient neurons are shorter than those from wild-type
neurons before treatment with 2-dGal. Based on these results,
we propose that defucosylation may disrupt synapsin function,
leading to its degradation and neurite retraction. Although
further studies will be needed to resolve whether synapsin
fucosylation stimulates or inhibits neurite outgrowth, these
results strongly support the notion that synapsin fucosylation
plays a role in modulating neuronal growth and morphology.
Our data also implicate other Fuc(1-2)Gal glycoproteins in the
regulation of neuronal morphology. We demonstrate that Fuc(1-
2)Gal carbohydrates are not limited to synapsin but are found on
several additional proteins in developing neurons. Expression of the
sugar andor these glycoproteins changes dramatically during the
course of neuronal development. We found that disruption of
synapsin fucosylation contributed, but was not fully sufficient, to
account for the striking neurite retraction induced by 2-dGal. For
instance, 2-dGal had stronger effects on neurite outgrowth at high
concentrations relative to deletion of the synapsin I gene, suggesting
that 2-dGal may disrupt the fucosylation of other Fuc(1-2)Gal
glycoproteins that influence neuronal morphology. Moreover,
2-dGal was still capable of inducing partial neurite retraction in
synapsin-deficient neurons and young cultured neurons where
synapsin expression is low (12). Thus, Fuc(1-2)Gal sugars appear
to modulate the functions of multiple proteins involved in neuronal
morphology and exert their effects via several distinct molecular
mechanisms.
Finally, our findings may shed light on behavioral and electro-
physiological studies implicating Fuc(1-2)Gal in long-term mem-
ory storage. Alterations in neuronal morphology, such as dynamic
changes in dendritic spine number and shape, occur duringmemory
consolidation and LTP (38, 39). Future studies will investigate
whether Fuc(1-2)Gal sugars and their associated glycoproteins
contribute to structural remodeling events that underlie synaptic
plasticity.
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